SUN PHARMA earnings and margin surge, know what is the investment strategy of brokerage houses

In the fourth quarter, SUN PHARMA saw a 4 percent growth in earnings and a 7 percent jump in margins, but the company’s profits were lower than expected.

In the last quarter of the financial year 2020-21, the net profit of the leading pharma company Sun Pharmaceuticals Industries increased more than double on an annual basis. Sun Pharma’s consolidated net profit stood at Rs 894.15 crore in Q4 as compared to Rs 399.84 crore in the same quarter last year.

The board of this has announced a dividend of Rs 2 per share for FY21. The company’s consolidated revenue from operations grew 4% to 8522.98 crores in the March quarter from Rs 8,184.94 crore in Q4 last year. Sun Pharma MD Dilip Shanghvi said FY21 was a very volatile year due to the Corona Wire epidemic. But despite all the challenges, the company recorded overall growth.

CLSA’s opinion on SUN PHARMA

CLSA has a buy rating on SUN PHARMA and set a share target of Rs 850. They raised the company’s FY22-23 EPS estimate by 1-3 percent. He says that the position has been strengthened in specialty products.

Opinion on CS SUN PHARMA

CS has given an underperform rating on SUN PHARMA and set a share target of Rs 525.

Opinions on SOR PHARMA by MORGAN STANLEY

MORGAN STANLEY has given an overweight rating on PHARMA and has fixed a target of Rs 705. He says that sales of every segment are expected to pick up in FY22. At the same time, there is a possibility of strong stock re-rating in the balance sheet.